CALIFORNIA RETINA CONSULTANTS

Innovative drug delivery platforms like gene therapy, the port delivery system (PDS), and encapsulated cell therapy (ECT) aim to enhance treatment durability and reduce patient burden for chronic retinal diseases, addressing issues of adherence and missed doses.

UNITY Biotechnology will host an in-person and virtual event on Oct 15, 2024, focusing on its Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) in DME. The event includes presentations on the senolytic therapeutic hypothesis, clinical development plans, and a retina expert roundtable. 24-week data expected Q1 2025, 36-week data Q2 2025.

UNITY Biotechnology will host an in-person and virtual event on October 15, 2024, focusing on its Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) in diabetic macular edema. The event includes presentations on the senolytic therapeutic hypothesis, clinical development plans, and a retina expert roundtable, followed by a live Q&A. 24-week data is expected in Q1 2025, with 36-week data in Q2 2025.

UNITY Biotechnology to host an in-person and virtual event on October 15, 2024, featuring ophthalmology KOLs and management. The event will focus on the Phase 2b ASPIRE study evaluating UBX1325 in diabetic macular edema (DME), with 24-week and 36-week data expected in Q1 and Q2 2025, respectively.

UNITY Biotechnology hosts in-person and virtual Ophthalmology Day on Oct 15, 2024, in NY, featuring KOLs and management discussing the Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) vs. aflibercept in DME. Expected 24-week data in Q1 2025, 36-week data in Q2 2025. Virtual attendees can access via UNITY's website.